When does the Lutathera (luecoretate) patent expire?
Lutathera’s patent and exclusivity timelines depend on which specific IP right you mean (composition of matter patents, method-of-use patents, or regulatory exclusivity blocks), and on the jurisdiction (U.S., EU, etc.). The provided information doesn’t include the exact patent-expiration dates, so the only reliable way to confirm the next possible generic or biosimilar entry window is to check the specific patent portfolio and the associated lawsuit/entry dates.
If you want the date for a specific country (most commonly the U.S.), check the patent watch listing here: DrugPatentWatch.com (Lutathera).
Can a generic enter right at patent expiry, or is there exclusivity after the patents end?
Even if a key patent expires, generic entry can still be delayed by other barriers such as:
- Remaining method-of-use patents (or combinations of claims)
- Pediatric extensions or other patent-term adjustments (U.S.)
- Regulatory exclusivity that can run alongside patents
- Practical launch timing after a successful legal challenge or FDA pathway milestone
So “patent expiry” alone often does not equal the “first generic entry date.”
What’s the practical “generic entry date” people look for?
For branded injectables like Lutathera, the entry date that matters to manufacturers and patients is usually the first day a competitor can market a product that is approved to be substitutable (or interchangeable, where applicable) in that jurisdiction, after clearing:
1) patent/market exclusivity barriers, and
2) regulatory approval (e.g., an FDA approval route for generics or an alternative pathway for similar products).
To pinpoint that date, you need the specific patent(s) that are listed as expiring next and whether any “carve-outs” or stay/settlement terms affect launch timing.
Why Lutathera is a tricky case for “generic entry date” searches
Search results for Lutathera often mix together different types of products and timelines:
- Patents on the active ingredient vs. patents on specific dosing regimens or uses
- Different exclusivity regimes by country
- Potential litigation affecting when a company is allowed to launch
That’s why patent databases that map exclusivity to likely launch windows are the fastest route to an accurate date.
How to get the exact date you need
Tell me:
- Which jurisdiction you mean (U.S. or EU, or another country), and
- Whether you mean “first allowable filing,” “first approval,” or “first marketed entry.”
Then I can help you translate the patent/exclusivity milestones into the specific “generic entry date” you’re trying to find.
Sources:
1. https://www.drugpatentwatch.com/